BRCA1 and triple-negative breast carcinoma: Consistent with our results, SIRT5 was shown to be overexpressed in human NSCLC (13), triple-negative breast cancer, breast cancer with BRCA1 mutation subtypes (17), CRC (15), and HCC (14).